Mayank Goyal1, Mohammed A Almekhlafi2, Liqiong Fan2, Bijoy K Menon2, Andrew M Demchuk2, Sharon D Yeatts2, Michael D Hill2, Thomas Tomsick2, Pooja Khatri2, Osama O Zaidat2, Edward C Jauch2, Muneer Eesa2, Tudor G Jovin2, Joseph P Broderick2. 1. Departments of Radiology and Clinical Neurosciences, Calgary Stroke Program, University of Calgary, Calgary, Alberta, Canada (M.G., M.A.A., B.K.M., A.M.D., M.D.H., M.E.); Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia (M.A.A.); Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.F., S.D.Y.); Departments of Neurology and Radiology, University of Cincinnati, Cincinnati, OH (T.T., P.K., J.P.B.); Department of Radiology, Medical College of Wisconsin, Milwaukee (O.O.Z.); Division of Emergency Medicine, Medical University of South Carolina, Charleston (E.C.J.); and Stroke Institute, University of Pittsburgh Medical Center, Pittsburgh, PA (T.G.J.). mgoyal@ucalgary.ca. 2. Departments of Radiology and Clinical Neurosciences, Calgary Stroke Program, University of Calgary, Calgary, Alberta, Canada (M.G., M.A.A., B.K.M., A.M.D., M.D.H., M.E.); Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia (M.A.A.); Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.F., S.D.Y.); Departments of Neurology and Radiology, University of Cincinnati, Cincinnati, OH (T.T., P.K., J.P.B.); Department of Radiology, Medical College of Wisconsin, Milwaukee (O.O.Z.); Division of Emergency Medicine, Medical University of South Carolina, Charleston (E.C.J.); and Stroke Institute, University of Pittsburgh Medical Center, Pittsburgh, PA (T.G.J.).
Abstract
BACKGROUND:Meaningful delays occurred in the Interventional Management of Stroke (IMS) III trial. Analysis of the work flow will identify factors contributing to the in-hospital delays. METHODS AND RESULTS: In the endovascular arm of the IMS III trial, the following time intervals were calculated: stroke onset to emergency department arrival; emergency department to computed tomography (CT); CT to intravenous tissue plasminogen activator start; intravenous tissue plasminogen activator start to randomization; randomization to groin puncture; groin puncture to thrombus identification; thrombus identification to start of endovascular therapy; and start of endovascular therapy to reperfusion. The effects of enrollment time, CT angiography use, interhospital transfers, and intubation on work flow were evaluated. Delays occurred notably in the time intervals from intravenous tissue plasminogen activator initiation to groin puncture (median 84 minutes) and start of endovascular therapy to reperfusion (median 85 minutes). The CT to groin puncture time was significantly shorter during working hours than after. Times from emergency department to reperfusion and groin puncture to reperfusion decreased over the trial period. Patients withCT angiography had shorter emergency department to reperfusion and onset to reperfusion times. Transfer of patients resulted in a longer onset to reperfusion time compared with those treated in the same center. Age, sex, National Institutes of Health Stroke Scale score, and intubation did not affect delays. CONCLUSIONS: Important delays were identified before reperfusion in the IMS III trial. Delays decreased as the trial progressed. Use of CT angiography and endovascular treatment in the same center were associated with time savings. These data may help in optimizing work flow in current and future endovascular trials. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
RCT Entities:
BACKGROUND: Meaningful delays occurred in the Interventional Management of Stroke (IMS) III trial. Analysis of the work flow will identify factors contributing to the in-hospital delays. METHODS AND RESULTS: In the endovascular arm of the IMS III trial, the following time intervals were calculated: stroke onset to emergency department arrival; emergency department to computed tomography (CT); CT to intravenous tissue plasminogen activator start; intravenous tissue plasminogen activator start to randomization; randomization to groin puncture; groin puncture to thrombus identification; thrombus identification to start of endovascular therapy; and start of endovascular therapy to reperfusion. The effects of enrollment time, CT angiography use, interhospital transfers, and intubation on work flow were evaluated. Delays occurred notably in the time intervals from intravenous tissue plasminogen activator initiation to groin puncture (median 84 minutes) and start of endovascular therapy to reperfusion (median 85 minutes). The CT to groin puncture time was significantly shorter during working hours than after. Times from emergency department to reperfusion and groin puncture to reperfusion decreased over the trial period. Patients with CT angiography had shorter emergency department to reperfusion and onset to reperfusion times. Transfer of patients resulted in a longer onset to reperfusion time compared with those treated in the same center. Age, sex, National Institutes of Health Stroke Scale score, and intubation did not affect delays. CONCLUSIONS: Important delays were identified before reperfusion in the IMS III trial. Delays decreased as the trial progressed. Use of CT angiography and endovascular treatment in the same center were associated with time savings. These data may help in optimizing work flow in current and future endovascular trials. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
Authors: Osama O Zaidat; Marc A Lazzaro; Rishi Gupta; Peter A Rasmussen; Donald F Frei; Mayank Goyal Journal: J Neurointerv Surg Date: 2013-07-06 Impact factor: 5.836
Authors: Mayank Goyal; Michel Shamy; Bijoy K Menon; Jeffrey L Saver; Hans-Christoph Diener; J Mocco; Vitor Mendes Pereira; Tudor G Jovin; Osama Zaidat; Elad I Levy; Antoni Davalos; Andrew Demchuk; Michael D Hill Journal: Stroke Date: 2013-11-12 Impact factor: 7.914
Authors: Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: Circulation Date: 2011-02-10 Impact factor: 29.690
Authors: Mohammed A Almekhlafi; Muneer Eesa; Bijoy K Menon; Andrew M Demchuk; Mayank Goyal Journal: J Neurointerv Surg Date: 2012-11-03 Impact factor: 5.836
Authors: J L Saver; R Jahan; E I Levy; T G Jovin; B Baxter; R Nogueira; W Clark; R Budzik; O O Zaidat Journal: Int J Stroke Date: 2012-11-06 Impact factor: 5.266
Authors: Atte Meretoja; Louise Weir; Melissa Ugalde; Nawaf Yassi; Bernard Yan; Peter Hand; Melinda Truesdale; Stephen M Davis; Bruce C V Campbell Journal: Neurology Date: 2013-08-14 Impact factor: 9.910
Authors: D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk Journal: AJNR Am J Neuroradiol Date: 2018-05-17 Impact factor: 3.825
Authors: A Vagal; L D Foster; B Menon; A Livorine; J Shi; E Qazi; S D Yeatts; A M Demchuk; M D Hill; T A Tomsick; M Goyal Journal: AJNR Am J Neuroradiol Date: 2016-03-17 Impact factor: 3.825
Authors: Ryan A McTaggart; Shadi Yaghi; Shawna M Cutting; Morgan Hemendinger; Grayson L Baird; Richard A Haas; Karen L Furie; Mahesh V Jayaraman Journal: JAMA Neurol Date: 2017-07-01 Impact factor: 18.302
Authors: Feras Akbik; Joshua A Hirsch; Pedro Telles Cougo-Pinto; Ronil V Chandra; Claus Z Simonsen; Thabele Leslie-Mazwi Journal: Curr Treat Options Cardiovasc Med Date: 2016-05